<DOC>
	<DOC>NCT00922428</DOC>
	<brief_summary>The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders.</brief_summary>
	<brief_title>PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders</brief_title>
	<detailed_description>The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders of different aetiology and localisation, displaying a variety of symptoms. Efficacy and tolerability of the drug will be assessed. Special regard will be taken to the administration management in relation to the Summary of Product Characteristics (SmPC).</detailed_description>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Due to the design as an Observational Study no inclusion or exclusion criteria for therapy are named. The included patient group is described under "Cohort / Group". Observational Criteria (=inclusion criteria for documentation): Males and females At least 18 years old Rheumatic disease with accompanying symptoms, e.g. arthralgia, myalgia, lumbago etc. Exclusion criteria for documentation: younger than 18 years no Rheumatic disease with accompanying symptoms, e.g. arthralgia, myalgia, lumbago etc. no treatment with PASCOEAgil HOMInjektopas</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>rheumatism</keyword>
	<keyword>arthralgia</keyword>
	<keyword>myalgia</keyword>
	<keyword>lumbago</keyword>
	<keyword>homoeopathy</keyword>
	<keyword>injection</keyword>
	<keyword>PASCOE-Agil HOM Injektopas</keyword>
	<keyword>efficacy</keyword>
	<keyword>tolerability</keyword>
	<keyword>acceptance</keyword>
	<keyword>safety</keyword>
</DOC>